title: Suicide and depression in a patient with psoriasis receiving adalimumab: the role of the dermatologist.
abstract: A 53-year-old man took his own life while receiving biological therapy with the tumour necrosis factor-α inhibitor adalimumab for severe psoriasis. The patient had a psychiatric history and a 32-year history of variable unstable psoriasis. Reported suicide in patients with psoriasis receiving adalimumab is rare (only one other reported case). It is important, however, to recognize the effects of skin disease on the mental health of vulnerable patients receiving biological agents. Patients will benefit from a more holistic approach that includes both dermatological and psychological assessment and treatment.
authors.affiliation: Department of General Medicine, Whipps Cross Hospital, London, UK.
authors.forename: R
authors.initials: R
authors.lastname: Ellard
authors.forename: A
authors.initials: A
authors.lastname: Ahmed
authors.forename: R
authors.initials: R
authors.lastname: Shah
authors.forename: A
authors.initials: A
authors.lastname: Bewley
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D001688:Biological Products / Q000009:adverse effects*; D003866:Depressive Disorder / Q000209:etiology*; D003880:Dermatology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010819:Physician's Role; D011565:Psoriasis / Q000188:drug therapy / Q000523:psychology; D012307:Risk Factors; D013405:Suicide
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D000068879:Adalimumab